Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 152.47 USD -0.5%
Market Cap: 367B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Johnson & Johnson

Revenue
87.7B USD
Cost of Revenue
-27B USD
Gross Profit
60.7B USD
Operating Expenses
-36.5B USD
Operating Income
24.2B USD
Other Expenses
-9.5B USD
Net Income
14.7B USD

Margins Comparison
Johnson & Johnson Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Johnson & Johnson
NYSE:JNJ
368.4B USD
69%
28%
17%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
761.8B USD
81%
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
85%
44%
35%
US
Merck & Co Inc
NYSE:MRK
250.9B USD
77%
34%
19%
CH
Roche Holding AG
SIX:ROG
208.8B CHF
73%
32%
20%
CH
Novartis AG
SIX:NOVN
181.2B CHF
75%
29%
33%
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP
82%
21%
13%
IE
Endo International PLC
LSE:0Y5F
155B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
151.8B USD
71%
22%
7%
Country US
Market Cap 368.4B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
17%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 761.8B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 250.9B USD
Gross Margin
77%
Operating Margin
34%
Net Margin
19%
Country CH
Market Cap 208.8B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country CH
Market Cap 181.2B CHF
Gross Margin
75%
Operating Margin
29%
Net Margin
33%
Country UK
Market Cap 158.6B GBP
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country IE
Market Cap 155B USD
Gross Margin
68%
Operating Margin
11%
Net Margin
-126%
Country US
Market Cap 151.8B USD
Gross Margin
71%
Operating Margin
22%
Net Margin
7%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Johnson & Johnson Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Johnson & Johnson
NYSE:JNJ
368.4B USD
20%
8%
18%
13%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
761.8B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
89%
27%
75%
35%
US
Merck & Co Inc
NYSE:MRK
250.9B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
208.8B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
181.2B CHF
35%
16%
20%
15%
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP
17%
6%
14%
12%
IE
Endo International PLC
LSE:0Y5F
155B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
151.8B USD
5%
2%
7%
8%
Country US
Market Cap 368.4B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 761.8B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.3T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 250.9B USD
ROE
28%
ROA
11%
ROCE
25%
ROIC
20%
Country CH
Market Cap 208.8B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country CH
Market Cap 181.2B CHF
ROE
35%
ROA
16%
ROCE
20%
ROIC
15%
Country UK
Market Cap 158.6B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country IE
Market Cap 155B USD
ROE
70%
ROA
-51%
ROCE
5%
ROIC
6%
Country US
Market Cap 151.8B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
8%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top